ARS Pharmaceuticals, Inc. filed 3 current reports with the SEC under Item 5.02, which covers directors and officers leaving or being appointed, the latest on 2026-07-17. Between them they name 2 people. Each change below is quoted from the filing and linked to it.
Every change, newest first
Departing: Richard Lowenthal, Director
On July 15, 2026, Richard Lowenthal resigned as a member of the Board of Directors (the "Board") of ARS Pharmaceuticals, Inc. (the "Company"), effective immediately.
Departing: Sarina Tanimoto, Chief Medical Officer
Additionally, on July 15, 2026, Sarina Tanimoto, M.D., the Company's Chief Medical Officer, ceased employment with the Company under conditions constituting a termination without cause.
Reported
On July 7, 2026, the Board of Directors (the "Board") of ARS Pharmaceuticals, Inc. (the "Company") appointed the Company's current President Donn Casale as the Company's Chief Executive Officer, effective immediately, replacing Richard Lowenthal in such capacity.
Reported
On May 12, 2026, the Board of Directors of ARS Pharmaceuticals, Inc., a Delaware corporation (the "Company"), based in part on the recommendation of Richard Lowenthal, the Company's Chief Executive Officer, appointed Donn Casale as the Company's President effective as of the date he commences employment with the Company, which date is expected to be June 1, 2026.
Find people with the same kind of experience as the Director at ARS Pharmaceuticals, Inc., with the record behind each one.
Find candidates like Director at ARS Pharmaceuticals, Inc.New leaders review vendors and budgets in their first months. Get an alert the next time ARS Pharmaceuticals, Inc. is in the news or changes leadership.
Get an alert when ARS Pharmaceuticals, Inc. changes leadershipTools for this story
Each opens in a new tab, filled in for ARS Pharmaceuticals, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.